|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 27, 2014 ) Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
The 2013 base-year market sales of asthma products in Japan were $1.7 billion. A dip in sales caused by the Singulair patent expiry in 2013, as well as the patent expiry of the best-selling ICS/LABA FDCs, GSK’s Advair and AstraZeneca’s Symbicort, will be offset by eight pipeline product launches, seven of which are targeted biologics. Despite the fact that the target patient pool for these biologic therapies will be relatively limited, as they will target only specific subpopulations of severe asthmatics, they will fulfill some of the major unmet needs for the treatment of severe asthmatics who do not respond to conventional treatment with the ICS and ICS/LABA therapies.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=213051 .
Scope
• Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Japan from 2013-2023.
• Analysis of the impact of key events as well the drivers and restraints affecting the Japan Asthma market.
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2013-2023 in Japan.
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=213051 . (Report Price: Single User License – US$4995 and Corporate User License – US$14985)
Table of Contents
1 Table of Contents 5
1.1 List of Tables9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 18
3.1.3 Prognosis 20
3.1.4 Quality of Life 20
3.2 Symptoms 21
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Diagnosis 22
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 23
4.1.3 Clinical Practice 24
4.2 Japan 28
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 32
5.3 Inhaled Corticosteroids 36
5.3.1 Flovent (fluticasone propionate) 36
5.3.2 Pulmicort (budenoside) 40
5.3.3 Other Inhaled Corticosteroids 44
5.4 Long-Acting Beta-Agonists 45
5.4.1 Overview 45
5.5 Inhaled Corticosteroids/Long-Acting Beta-Agonists 46
5.5.1 Advair (fluticasone propionate/salmeterol xinafoate) 46
5.5.2 Symbicort (budenoside/formoterol fumarate) 52
5.5.3 Breo Ellipta (fluticasone furoate/vilanterol trifenatate) 55
5.5.4 Flutiform (fluticasone propionate/formoterol fumarate) 59
5.6 Leukotriene Modifiers 63
5.6.1 Singulair (montelukast) 63
5.6.2 Other Leukotriene Modifiers 67
5.7 Short-Acting Beta-Agonists 68
5.7.1 Overview 68
5.7.2 Efficacy 69
5.7.3 Safety 70
5.8 Targeted Therapies 71
5.8.1 Xolair (omalizumab) 71
5.9 Anticholinergics 74
5.9.1 Spiriva (tiotropium bromide) 74
6 Unmet Need and Opportunity 79
6.1 Overview 79
6.2 Personalized Therapies to Control Severe Asthma 80
6.2.1 Unmet Need 80
6.2.2 Gap Analysis 81
6.2.3 Opportunity 81
6.3 Better Patient Compliance 81
6.3.1 Unmet Need 81
6.3.2 Gap Analysis 82
6.3.3 Opportunity 83
6.4 Lower Cost of Asthma Medications 83
6.4.1 Unmet Need 83
6.4.2 Gap Analysis 84
6.4.3 Opportunity 84
6.5 Proper Diagnosis of Asthma in Children 84
6.5.1 Unmet Need 84
6.5.2 Gap Analysis 85
6.5.3 Opportunity 85
7 Pipeline Assessment 86
7.1 Overview 86
7.2 Promising Drugs in Clinical Development 88
7.2.1 Fluticasone furoate 89
7.2.2 Cinquil (reslizumab) 93
7.2.3 Bosatria (mepolizumab) 98
7.2.4 Lebrikizumab 103
7.2.5 Benralizumab 108
7.2.6 Dupilumab 113
7.2.7 Quilizumab 118
7.2.8 Tralokinumab 122
8 Market Outlook 127
8.1 Japan 127
8.1.1 Forecast 127
8.1.2 Key Events 132
8.1.3 Drivers and Barriers - Global Issues 132
8.1.4 Drivers and Barriers 135
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
